Ligand Pharmaceuticals (LGND) News Today $100.91 +0.72 (+0.72%) Closing price 04:00 PM EasternExtended Trading$98.28 -2.63 (-2.60%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Bank of America Corp DE raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,439 shares of the biotechnology company's stock after purchasinMay 25, 2025 | marketbeat.comCastleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Castleark Management LLC cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,113 shares of the biotechMay 23, 2025 | marketbeat.comAnalysts Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target at $146.14May 19, 2025 | americanbankingnews.comGraham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Graham Capital Management L.P. acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,998 shares of the bioMay 18, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by BrokeragesShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelMay 18, 2025 | marketbeat.comDeutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Deutsche Bank AG raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 289,052 shares of the biotechnology company'May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Janus Henderson Group PLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,015,023 shares of thMay 15, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.comStockNews.com cut Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.May 15, 2025 | marketbeat.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in StockMay 14, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Northern Trust CorpNorthern Trust Corp increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,957 shares of the biotechnology comMay 13, 2025 | marketbeat.comLGND: 1Q:25 ResultsMay 12, 2025 | msn.comClark Capital Management Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Clark Capital Management Group Inc. lifted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 44.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,277 shares of the bMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Driehaus Capital Management LLC raised its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 70.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 162,771 shares of the biotechnology company's stock after buyingMay 11, 2025 | marketbeat.comBaird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Baird Financial Group Inc. increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 8.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,207 shares of the biotechnMay 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.110. The company also issued revenue guidance of $180.0 millionillion-$200.0 millionillion, compared to the consensus estimate of $191.3 millionillion.May 10, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...May 9, 2025 | finance.yahoo.comQ1 2025 Ligand Pharmaceuticals Inc Earnings Call TranscriptMay 9, 2025 | gurufocus.comLigand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comLigand Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comLigand Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comMariner LLC Purchases Shares of 2,574 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Mariner LLC acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,574 shares of the biotechnologyMay 8, 2025 | marketbeat.comLigand Pharmaceuticals Q1 2025 Earnings PreviewMay 7, 2025 | seekingalpha.comDimensional Fund Advisors LP Buys 16,003 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Dimensional Fund Advisors LP lifted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 723,019 shares of the biotechnology company's stockMay 3, 2025 | marketbeat.comLigand Pharmaceuticals (LGND) Projected to Post Earnings on ThursdayLigand Pharmaceuticals (NASDAQ:LGND) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-ligand-pharmaceuticals-incorporated-stock/)May 3, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Raymond James Financial Inc. bought a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 21,830 shares of the biotechnology company's stock, valued at approximatMay 2, 2025 | marketbeat.comLigand to Participate in May Investor ConferencesMay 1, 2025 | globenewswire.comIs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?April 30, 2025 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Wells Fargo & Company MNWells Fargo & Company MN boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 29.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,220 shaApril 30, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Barclays PLCBarclays PLC cut its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 8.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,972 shares of the bApril 29, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Boosted by Penn Capital Management Company LLCPenn Capital Management Company LLC lifted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,430 shares of the bApril 26, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)XTX Topco Ltd purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,067 shares of the biApril 26, 2025 | marketbeat.comLigand to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Uniplan Investment Counsel Inc.Uniplan Investment Counsel Inc. increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 28.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,155 shares of the biotechApril 24, 2025 | marketbeat.comLGND: Pelthos To Become Public CompanyApril 23, 2025 | msn.comJPMorgan Chase & Co. Has $4.05 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)JPMorgan Chase & Co. decreased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,761 shares of the biotechnoApril 22, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by AnalystsLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Buy" from the seven research firms that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target amApril 22, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Invesco Ltd.Invesco Ltd. boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 194,355 shares of theApril 21, 2025 | marketbeat.comRevisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100April 20, 2025 | seekingalpha.comNFJ Investment Group LLC Purchases New Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)NFJ Investment Group LLC acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,847 shares of the biotechnologyApril 20, 2025 | marketbeat.comLigand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel TherapeuticsApril 18, 2025 | finanznachrichten.deChannel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s ElatedApril 18, 2025 | msn.comLigand Pharmaceuticals (LGND) and Channel Therapeutics Announce Merger to Form Pelthos ...April 17, 2025 | gurufocus.comLigand Subsidiary Pelthos Therapeutics to Combine with Channel TherapeuticsApril 17, 2025 | globenewswire.comTownsquare Capital LLC Purchases 4,726 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Townsquare Capital LLC raised its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 15.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,539 shares of the biotechnology company's stockApril 17, 2025 | marketbeat.comGeode Capital Management LLC Buys 10,171 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Geode Capital Management LLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,441 shares of theApril 16, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Upgraded at StockNews.comStockNews.com raised shares of Ligand Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday.April 16, 2025 | marketbeat.comJ&J kicks off pharma earnings season with guidance raise amid looming tariffsApril 15, 2025 | msn.comGranite Investment Partners LLC Sells 2,463 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Granite Investment Partners LLC reduced its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 115,538 shares of the biotechnology company's stock after seApril 15, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 17.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,600 shares of the biotechnology company's stockApril 14, 2025 | marketbeat.com Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼1.600.88▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼35▲LGND Articles Average Week Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today RGEN News Today MDGL News Today IONS News Today ALKS News Today BCRX News Today FOLD News Today CLDX News Today MNKD News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
